Coherus Oncology, Inc. - Common Stock (CHRS)

CUSIP: 19249H103

Q4 2017 13F Holders as of 31 Dec 2017

Holder snapshot 7 signals
Share change
+2,562,125
Put/Call ratio
98%
SEC-reported price per share
$8.80
Indexed holders
92
Value change
+$17,238,403
Number of buys
49
Open additional details 1 more signal available
Number of sells
39
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
154,050,897

Security key

19249H103

Report period

Q4 2017

Indexed institutions

92

Top holders

10

Ownership snapshot

Top reported holders of CHRS - Coherus Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
FMR LLC
Disclosed value leader
FMR LLC
Comparable rows
0/15
Latest evidence
30 Sep 2017
13F Highest disclosed value: $102,880,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

FMR LLC has the largest disclosed position value at $102.88M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens FMR LLC's linked filing trail.
Disclosed position value Top 5
FMR LLC $102.88M
Temasek Holdings (Private) Ltd $87.52M
WELLINGTON MANAGEMENT GROUP LLP $83.87M
BlackRock Finance, Inc. $43.76M
Kohlberg Kravis Roberts & Co. L.P. $40.78M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
FMR LLC
13F
Company
13F
—
denominator unverified
$102,880,000
7,706,310 shares
— 30 Sep 2017
Temasek Holdings (Private) Ltd
13F
Company
13F
—
denominator unverified
$87,524,000
6,556,116 shares
— 30 Sep 2017
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$83,872,000
6,282,588 shares
— 30 Sep 2017
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$43,761,000
3,278,049 shares
— 30 Sep 2017
Kohlberg Kravis Roberts & Co. L.P.
13F
Company
13F
—
denominator unverified
$40,785,000
3,055,055 shares
— 30 Sep 2017
VANGUARD GROUP INC
13F
Company
13F
—
denominator unverified
$32,943,000
2,467,566 shares
— 30 Sep 2017
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q4 2017

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
92
Shares
49,467,518
Indexed holders
92
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q4 2017 vs Q3 2017 Across Filers

Q3 2017 indexed holders
90
Q4 2017 indexed holders
92
Indexed holder difference
2
Investor Q3 2017 Shares Q4 2017 Shares Share Diff Share Chg % Q3 2017 value Q4 2017 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .